A detailed history of Pdt Partners, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 21,426 shares of STOK stock, worth $289,465. This represents 0.03% of its overall portfolio holdings.

Number of Shares
21,426
Holding current value
$289,465
% of portfolio
0.03%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.12 - $14.17 $88,275 - $303,606
21,426 New
21,426 $289,000
Q2 2023

Aug 14, 2023

SELL
$7.93 - $13.82 $97,094 - $169,212
-12,244 Reduced 34.17%
23,592 $250,000
Q1 2023

May 15, 2023

SELL
$7.65 - $10.38 $35,388 - $48,017
-4,626 Reduced 11.43%
35,836 $298,000
Q4 2022

Feb 14, 2023

BUY
$7.07 - $15.69 $175,696 - $389,912
24,851 Added 159.19%
40,462 $373,000
Q3 2022

Nov 14, 2022

SELL
$12.56 - $22.53 $101,221 - $181,569
-8,059 Reduced 34.05%
15,611 $200,000
Q2 2022

Aug 15, 2022

BUY
$10.36 - $23.93 $245,221 - $566,423
23,670 New
23,670 $313,000
Q3 2021

Nov 15, 2021

SELL
$23.65 - $34.44 $604,352 - $880,079
-25,554 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$30.53 - $41.09 $576,925 - $776,477
18,897 Added 283.87%
25,554 $860,000
Q1 2021

May 17, 2021

BUY
$36.08 - $69.81 $240,184 - $464,725
6,657 New
6,657 $259,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $533M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.